Optimal says PAT tech can increase productivity without facility expansion

PAT technology has been focused on as much of the work can be done remotely, helping with the current restrictions

Process Analytical Technology (PAT) and factory automation can help pharmaceutical manufacturers meet the rising demands of global healthcare production.

Today's global public health situation is putting pharmaceutical businesses under enormous pressure to deliver innovative and existing tests and treatments as quickly as possible. Optimal's Process Analytical Technology (PAT) and factory automation can support pharmaceutical manufacturers to shorten scale-up times dramatically and increase productivity without expanding their facilities.

PAT is a key ally to pharmaceutical manufacturers, who are now being asked to substantially increase their production capacity and deliver new and existing products in much higher volumes. The urgency with which pharma businesses need to meet the rising demands of global healthcare production doesn't provide sufficient time for them to significantly expand their operations by increasing their manufacturing footprint. There is, however, a solution.

The advantages of PAT are nothing new. By measuring the quality attributes of a product in real time and empowering operators to manually or automatically control critical process parameters accordingly, PAT eliminates the need to stop every time a manufacturing stage has been completed to conduct quality controls. This, in turn, cuts cycle and scale up times, eradicates off-spec products and vastly reduces work in progress, whilst supporting real-time release testing.

Furthermore, in bio-processing technology - a key production method for the current crisis - PAT has a proven track record of being able to triple the production of the upstream process by maintaining it at its optimum level.

PAT can also improve the quality and yield of the downstream process by using real time quality determinations.

To further streamline manufacturing operations, automation of all forms - be it process control, robotics, special purpose machinery or vision systems can be applied stand alone or in combination with PAT, to either increase the productivity of existing manufacturing hardware else bring 'mothballed' hardware back to life.

As a bonus, much of the work can be executed remotely, with many site tasks conducted remotely using the Internet. Therefore, many projects can proceed despite current restrictions.

The key fact, at these difficult times, is that businesses are able to produce more from their existing manufacturing infrastructure - be it for the production of pharmaceuticals or test kits.

With over 30 years of experience in providing the pharmaceutical sector with regulatory compliant automated solutions as well as the PAT knowledge management platform, synTQ, Optimal can support pharmaceutical manufacturers. These can benefit from a comprehensive one-stop-shop for the implementation of suitable PAT strategies as well as bespoke factory automation setups to help promptly and effectively address current global healthcare challenges.

Martin Gadsby, Director at Optimal Industrial Technologies, said: "By implementing a PAT-driven, fully automated approach to R&D and manufacturing, businesses in the pharmaceutical sector can greatly improve throughput, in addition to increasing product quality and meeting regulatory compliance."

Gadsby explained: "These elements are currently playing an increasingly crucial role. We recognise that the pharmaceutical sector is facing an unprecedented global challenge, and we will do all we can to support their efforts."

"The proof is in the balance sheet. Several of our customers, who have already adopted the strategy of using synTQ and bespoke automation solutions to control their processes, have announced that they are ready to accelerate their manufacturing capabilities, as well as being able to start trials of new medicines sooner," Gadsby added.

Companies